A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Brexanolone (Primary)
  • Indications Status epilepticus
  • Focus Registrational; Therapeutic Use
  • Acronyms STATUS
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 09 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 09 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
    • 07 Aug 2017 According to a SAGE Therapeutics media release, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top